| Literature DB >> 8943861 |
T W McLean1, S Ringold, D Neuberg, K Stegmaier, R Tantravahi, J Ritz, H P Koeffler, S Takeuchi, J W Janssen, T Seriu, C R Bartram, S E Sallan, D G Gilliland, T R Golub.
Abstract
Polymerase chain reaction-based screening of childhood acute lymphoblastic leukemia (ALL) samples showed that a TEL/AML1 fusion transcript was detected in 27% of all cases, representing the most common known gene rearrangement in childhood cancer. The TEL/AML1 fusion results from a t(12;21)(p13;q22) chromosomal translocation, but was undetectable at the routine cytogenetic level. TEL/AML1-positive patients had exclusively B-lineage ALL, and most patients were between the ages of 2 and 9 years at diagnosis. Only 3/89 (3.4%) adult ALL patients were TEL/AML1-positive. Most importantly, TEL/AML1-positive children had a significantly lower rate of relapse compared with TEL/AML1-negative patients (0/22 v 16/54, P = .004). Co-immunoprecipitation experiments demonstrated that TEL/AML-1 formed homodimers in vitro, and heterodimerized with the normal TEL protein when the two proteins were expressed together. The elucidation of the precise mechanism of transformation by TEL/AML1 and the role of TEL/AML1 testing in the treatment of childhood ALL will require additional studies.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8943861
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113